This site is intended only for healthcare professionals in Hong Kong SAR.

Our medicinesOur medicinesBesponsaCibinqoCresembaEliquisEnbrelIbranceLorviquaNgenlaNurtecPaxlovidPrevenar20PristiqTalzennaVizimproVyndamaxXeljanzZaviceftaSee All productsPfizer Hong Kong Price ListTherapy areasTherapy areasMultiple MyelomaNon-Small-Cell Lung CancerRespiratory Syncytial VirusTransthyretin AmyloidosisSearch



Sign InLog Out
Explore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usPfizer medical information



About CIBINQOEfficacyEfficacyOverviewEfficacy of CIBINQO + Medicated TopicalsEfficacy of CIBINQO Without Medicated TopicalsReduction in Risk of FlaresLong-term Efficacy ResultsBefore and After PhotosGlossarySafetySafetySafety ProfileSafety ConsiderationsLab AbnormalitiesDosing & MonitoringDosing &
DosingLab Monitoring
Support & ResourcesSupport & ResourcesEventsMaterialsVideos

Click here for CIBINQO Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Lab MonitoringScreening and lab monitoring with CIBINQO¹

An appropriate CIBINQO patient should meet all of the following:
• Platelets ≥150 × 103/mm3
• Absolute lymphocyte count (ALC) ≥0.5 × 103/mm3
• Absolute neutrophil count (ANC) ≥1.2 × 103/mm3
• Haemoglobin (Hb) ≥10 g/dL

Serious infections:

  • Treatment must not be initiated in patients with an active, serious systemic infection
  • If a patient develops a serious infection, sepsis, or opportunistic infection, dose interruption should be considered until the infection is controlled


  • Use of live, attenuated vaccines should be avoided during or immediately prior to treatment. Prior to initiating treatment with this medicinal product, it is recommended that patients be brought up to date with all immunisations, including prophylactic herpes zoster vaccinations, in agreement with current immunisation guidelines


  • Patients should be screened for tuberculosis (TB) before starting treatment and yearly screening for patients in highly endemic areas for TB should be considered. CIBINQO must not be given to patients with active TB. For patients with a new diagnosis of latent TB or prior untreated latent TB, preventive therapy for latent TB should be started prior to initiation of CIBINQO

Viral reactivation:

  • Screening for viral hepatitis should be performed in accordance with clinical guidelines before starting therapy and during therapy with CIBINQO
ALC=absolute lymphocyte count; ANC=absolute neutrophil count; Hb=haemoglobin.Review Lab AbnormalitiesLoading
Explore more Safety Across Clinical Trials

Consistent safety profile with >3100 patients studied across JADE clinical trials1–7

See Safety Profile Loading
Disclaimer: CIBINQO is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.1References:CIBINQO® (abrocitinib) Prescribing Information. Pfizer Corporation Hong Kong Limited: Version September 2022.Bieber T, Simpson EL, Silverberg JI, et al; for the JADE COMPARE Investigators. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101-1112.Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255-266.
Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863-873.
Blauvelt A, Silverberg JI, Lynde CW, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol. 2022;86(1):104-112. 
Simpson EL, Silverberg JI, Nosbaum A, et al. Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program. Am J Clin Dermatol. 2021;22(5):693-707.
Cork MJ, Deleuran MS, Geng B, et al. Abrocitinib treatment in patients with moderate-to-severe atopic dermatitis: safety of abrocitinib stratified by age. Abstract 593. Presented at: European Academy of Dermatology and Venereology 30th Congress—2021 Anniversary Edition; 29 September-2 October 2021.
Dosing & Monitoring 

Ready to get a patient started?

The CIBINQO Prescriber Guide can help.

Download Prescriber Guide Loading

Patient safety is of paramount importance throughout the life cycle of a medicine - and pharmaceutical companies have ethical and regulatory responsibilities to monitor the safety of the products they sell for as long as they are used by consumers anywhere in the world. The Drug Safety Unit at Pfizer Corporation Hong Kong Limited. address product experience reports including adverse events. If you have any experience pertinent to the above, please contact us at (852) 2811 9711 as soon as possible.

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

This site is intended only for healthcare professionals resident in to Hong Kong. If you are a member of the public wishing to access information on a specific medicine, please visit


The information provided in this site is intended only for Health Professionals who reside in Hong Kong, and the products discussed herein may have different product labeling in different countries/regions. The site is for information purpose only, and nothing herein shall be construed as providing any kind of medical advice or recommendation or product promotion. Pfizer Corporation Hong Kong Limited is a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.


Copyright© 2023 Pfizer Corporation Hong Kong Limited. All rights reserved.

PP-UNP-HKG-0116 MAY 2023

You are leaving the PfizerPro Hong Kong website

You are being directed to a third-party website:

Please note that this third-party website is not controlled by PfizerPro Hong Kong or subject to our privacy policy.

Thank you for visiting our site. We hope your visit was informative and enjoyable.
PP-UNP-HKG-0076. May 2023​​​​​​​